In response to cellular stress, p53 exerts its tumor suppressive effects such as apoptosis, cell cycle arrest, and cellular homeostasis through the induction of its target genes. On the other hand, Various tumors had p53 mutations, nevertheless renal cell carcinoma(RCC) had few p53 mutations. Previous study reported that p53 inactivated pathways affected the renal carcinogenesis. Other report showed that p53 expression pattern in immunohistochemistry analysis of tumor was associated prognosis of RCC. Therefore, we considered a possibility that p53 target gene might affect prognosis of RCC. We identified a novel p53 function, and examined whether the p53 target was useful as a prognostic factor of RCC.
INTRODUCTION AND OBJECTIVES:
In response to cellular stress, p53 exerts its tumor suppressive effects such as apoptosis, cell cycle arrest, and cellular homeostasis through the induction of its target genes. On the other hand, Various tumors had p53 mutations, nevertheless renal cell carcinoma(RCC) had few p53 mutations. Previous study reported that p53 inactivated pathways affected the renal carcinogenesis. Other report showed that p53 expression pattern in immunohistochemistry analysis of tumor was associated prognosis of RCC. Therefore, we considered a possibility that p53 target gene might affect prognosis of RCC. We identified a novel p53 function, and examined whether the p53 target was useful as a prognostic factor of RCC.
METHODS: To screen novel p53 target genes, we conducted cDNA microarray analysis using mRNAs isolated from HCT116 p53þ/þ and HCT116 p53-/-cells that were treated with 2 mg/ml of adriamycin (ADR). To investigate whether mRNA transcription was regulated by p53, we performed a reporter assay and a chromatin immunoprecipitation (ChIP) assay using U373MG cells. To evaluate the biosynthesis of myo-inositol by a novel p53 target, we performed myo-inositol (MI) assay using HEK293T cells that were transfected with plasmid expressing the p53 target, and using HCT116 p53þ/þ and HCT116 p53-/-cells that were treated with ADR. To examined whether it was useful as a prognosis of RCC, we performed the overall survival (OS) analysis and progression free survival (PFS) analysis using mRNA expression of the p53 target in primary RCC.
RESULTS: The result of cDNA microarray analysis indicated ISYNA1 as a novel candidate gene. We found p53 response elements in the promoter region and the seventh exon by results of reporter assay and ChIP assay. Therefore, we identified ISYNA1 as a novel p53 target. The results of MI assay showed that intracellular myo-inositol content in cells expressing ISYNA1. In addition, DNA damage significantly increased intracellular myo-inositol content in HCT116 p53þ/þ cells, but did not affect the myo-inositol content in HCT116 p53-/-cells. ISYNA1 mRNA expression in primary RCC were significantly correlated to OS and PFS ( p < 0.01 ).
CONCLUSIONS: We identified ISYNA1 as a novel p53 target gene, and unveiled to regulate intracellular myo-inositol content by p53-ISYNA1 pathway. Our findings shew that ISYNA1 mRNA expression in primary renal cancer was correlated to overall survival and progression free survival. Therefore, we considered that ISYNA1 might be useful as a novel prognostic factor for the post-operative metastasis. 
METHODS: We first studied a database in TCGA, including gene expression data from 606 primary ccRCC samples to examine the TR4 expression. To further confirm this clinical data in the various ccRCC cell lines (786-0, SW839 and Caki-1), we assayed TR4 expression and applied the Matrigel-coated Transwell invasion assay and 3D invasion assay to examine their invasion capacity. We then assayed its influences on the VM tube formation and cell invasion via altering the TR4 expression. To further dissect the molecular mechanism how TR4 could decrease the VIM expression, we first searched for potential TR4 response elements (TR4REs) on the VIM 5' promoter region using JASPAR database. We then applied the Chip-on in vivo binding assay to examine TR4 binding to these TR4REs. To verify how miR-490-3p can directly regulate VIM expression through targeting its 3'UTR, we identified some potential binding sites located on the 3'UTR of VIM-mRNA and applied the reporter assay with the pscheck2 vector carrying the wild type and mutant miRNA-target sites. To prove the above in vitro cell line data in the in vivo mouse model, we applied the orthotopic ccRCC xenograft mouse model. We generated stable clones of Caki-1 cells with luciferase expression with overexpressed TR4 and/ or overexpressed miR-490-3p as well as a control, with 8 mice/group (1: Scrþluc; 2: oeTR4þluc; 3: oemi490-3pþluc; and 4: oeTR4þoemi490-3pþluc). Tumor progressions were evaluated via the non-invasive in vivo imaging system (IVIS). IHC staining from these ccRCC xenograft tumors were also evaluated.
RESULTS: Here we provide the first preclinical study data showing that TR4 may play positive roles in RCC VM formation and metastasis. Mechanism dissection revealed that TR4 might increase the oncogene VIM expression via decreasing the miR-490-3p expression through direct binding to the TR4-response-elements (TR4REs) on the promoter region of miR-490-3p, which might then directly target the 3'UTR of VIM-mRNA to increase its protein expression. Preclinical studies using the in vivo mouse model with xenografted RCC Caki-1 cells also found that TR4 could promote the ccRCC VM and its associated metastasis via modulating the miR490-3p/VIM signals.
CONCLUSIONS: Our results from preclinical studies using multiple RCC cell lines and the in vivo mouse model all conclude that TR4 may play a key role to promote ccRCC VM formation and metastasis and targeting the newly identified TR4/miR-490-3p/VIM signals with small molecules may help us to develop a new therapeutic approach to better suppress the ccRCC metastasis. 
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MIR-144-3P PROMOTES CELL PROLIFERATION, METASTASIS, SUNITINIB RESISTANCE IN CLEAR CELL RENAL CELL CARCINOMA BY DOWNREGULATING ARID1A xiaoping zhang*, wen xiao, wu han, China, People's Republic of INTRODUCTION AND OBJECTIVES: We previously performed microRNA (miRNA) microarray to identify effective indicators of clear cell renal cell carcinoma (ccRCC) tissue samples and preoperative/postoperative plasma in which we identified miR-144-3p as an oncomiRNA. However, the molecular mechanism of miR-144-3p remains unclear. This study aims to explore the roles of miR-144-3p in the invasion, migration and Sunitinib-resistance in ccRCC and to elucidate the underlying mechanisms.
METHODS: Gain and loss of function approaches were used to investigate the cell proliferation, cycle distribution, clonogenicity, migration, invasion, chemosensitivity of miR-144-3p in vitro. The e1200 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 
